RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Nuventra Pharma Sciences, a specialty pharmaceutical consulting firm with global reach, today announced that Mark A. Bush, Ph.D. has been appointed to the role of Chief Scientific Officer (CSO). Dr. Bush had served as the Senior Director, Clinical Pharmacokinetics (PK) at Nuventra prior to assuming duties as CSO. Dr. Bill Wargin, who had been CSO since the company's inception, remains with the company in an emeritus position as Executive Vice President of Pharmacokinetics.
Dr. Bush received his Ph.D. in pharmacokinetics from The University of North Carolina at Chapel Hill in 1999. Prior to joining Nuventra, he served as Director, Clinical Pharmacokinetics for GlaxoSmithKline where he focused on the use of innovative study designs and quantitative analysis methodologies (e.g., non-compartmental PK analysis, population PK and PK/PD modeling and simulation) to support informed and efficient clinical development.
"Dr. Bush brings extensive knowledge of pharmacokinetics, pharmacodynamics, and pharmacometrics to his new position as Nuventra's CSO," said Geoffrey Banks, Ph.D., Nuventra's President and CEO, adding further, "I look forward to Nuventra's continued growth as an innovative leader in PK/PD and population PK under Dr. Bush's leadership."
In this new role, Dr. Bush will lead Nuventra's scientific initiatives and strategies for clients.
"Nuventra's consulting business is based on fundamentals of PK/PD science," said Dr. Bush, adding further, "our priority is to apply such PK/PD fundamentals to drug development programs for the benefit of clients and patients."
About Nuventra Pharma Sciences
Founded in 2008, Nuventra is the pharmaceutical industry's go-to resource for clinical pharmacology, pharmacokinetic, and pharmacometric consulting services. Nuventra gives pharmaceutical companies and CROs rare access to a hands-on team of industry-leading consultants experienced in complex studies and analyses. We embrace the notion that simplicity and clarity lead to good decisions by taking complex pharmacokinetic and pharmacometric principals and making them understandable and usable for common sense drug development. Nuventra's flexible business structure enables us to integrate with our clients and help them maximize the potential of clinical pharmacology studies and pharmacokinetic analyses to pave the way toward marketing approval. For more information, visit www.nuventra.com.
Nuventra Pharma Sciences
M. Alexander Shaw, COO, 1-888-615-5111